Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Zemmour

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Hematology (Amsterdam, Netherlands)|May 3, 2023
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphomaRobin Noel, Christophe Zemmour, Catalina Montes de Oca, et al.
Journal De Mycologie Medicale|January 24, 2026
Pronostic factors for survival in candidemia among onco-hematology patients: a single-center retrospective study during 10 yearsFlorian Cardona, Ferdinand Villetard, Christophe Zemmour, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritisMyew-Ling Toh, Jean-Yves Bonnefoy, Nathalie Accart, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient recordsMathilde Beaufils, Vincent Amodru, Manuel Tejeda, et al.
The Oncologist|May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer networkNicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, et al.
Cancer Research|October 4, 2017
JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid LeukemiaMaria De Grandis, Florence Bardin, Cyril Fauriat, et al.
Breast Cancer Research and Treatment|February 4, 2017
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional studyAlexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, et al.
Blood Advances|July 2, 2024
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AMLJulien M P Grenier, Céline Testut, Matthieu Bal, et al.
Gynecologic Oncology|July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer databaseAlexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Hematology (Amsterdam, Netherlands)|May 3, 2023
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphomaRobin Noel, Christophe Zemmour, Catalina Montes de Oca, et al.
Journal De Mycologie Medicale|January 24, 2026
Pronostic factors for survival in candidemia among onco-hematology patients: a single-center retrospective study during 10 yearsFlorian Cardona, Ferdinand Villetard, Christophe Zemmour, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritisMyew-Ling Toh, Jean-Yves Bonnefoy, Nathalie Accart, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient recordsMathilde Beaufils, Vincent Amodru, Manuel Tejeda, et al.
The Oncologist|May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer networkNicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, et al.
Cancer Research|October 4, 2017
JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid LeukemiaMaria De Grandis, Florence Bardin, Cyril Fauriat, et al.
Breast Cancer Research and Treatment|February 4, 2017
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional studyAlexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, et al.
Blood Advances|July 2, 2024
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AMLJulien M P Grenier, Céline Testut, Matthieu Bal, et al.
Gynecologic Oncology|July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer databaseAlexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
Pageof 5